Novel Organon Agent to Reverse Muscle Relaxation in Anesthesia - FDA Agreement on Phase 3 Development Plan

... Organon and the US Food and Drug Administration (FDA) have reached agreement on the clinical development plan that will allow Org 25969 - the first selective relaxant binding agent to reverse neuromuscular block - to enter Phase 3 studies... click link for more info. ...